Jennifer Doudna startup Azalea Therapeutics launches with $82Mnews2025-11-04T13:00:49+00:00November 4th, 2025|Endpoints News|
Swiss biotech CDR-Life returns to Boehringer Ingelheim to partner on autoimmune T cell engagernews2025-11-04T13:00:32+00:00November 4th, 2025|Endpoints News|
South Korean biotech sets up California startup to advance ADCsnews2025-11-04T12:00:25+00:00November 4th, 2025|Endpoints News|
Tempero halts substance use disorder drug, is ‘assessing strategic alternatives’news2025-11-03T12:01:54+00:00November 3rd, 2025|Endpoints News|
Evommune plans to raise about $150M in IPO for inflammatory diseasesnews2025-10-30T14:27:55+00:00October 30th, 2025|Endpoints News|
Tubulis upsizes Series C to $401M to ‘push the boundaries of ADCs’news2025-10-30T10:00:43+00:00October 30th, 2025|Endpoints News|
DNA-chopping enzyme that breaks up NETs may offer new way to fight autoimmune disease, early data from Neutrolis suggestnews2025-10-29T10:00:58+00:00October 29th, 2025|Endpoints News|
Startup launches with $80M and a plan to teach the immune system to make better Tregsnews2025-10-28T11:00:34+00:00October 28th, 2025|Endpoints News|
Hemab nabs $157M to finance the ‘ultimate coagulation disorder’ biotechnews2025-10-27T10:00:58+00:00October 27th, 2025|Endpoints News|
Halda reveals first clinical data of RIPTAC drug in prostate cancernews2025-10-24T18:13:58+00:00October 24th, 2025|Endpoints News|
